These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 515773)

  • 1. Agranulocytosis during combined procainamide and phenytoin therapy.
    Crook JE; Woosley RL; Leftwich RB; Natelson EA
    South Med J; 1979 Dec; 72(12):1599-601. PubMed ID: 515773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agranulocytosis, procainamide, and phenytoin.
    Fleet S
    Ann Intern Med; 1984 Apr; 100(4):616-7. PubMed ID: 6703561
    [No Abstract]   [Full Text] [Related]  

  • 3. Agranulocytosis associated with procainamide therapy--report of a case.
    Prince RA; Brown BT; Jacknowitz AI
    Am J Hosp Pharm; 1977 Dec; 34(12):1362-5. PubMed ID: 596390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization to procainamide.
    Ream CR; Barrera R
    J Med Soc N J; 1970 Mar; 67(3):107-10. PubMed ID: 5264623
    [No Abstract]   [Full Text] [Related]  

  • 5. [Problems of evaluating rare adverse drug reactions using as an example agranulocytosis induced by anti-arrhythmia agents].
    Knipping W
    Med Klin; 1980 Feb; 75(3):108-15. PubMed ID: 7374607
    [No Abstract]   [Full Text] [Related]  

  • 6. Procainamide and phenytoin. Comparative study of their antiarrhythmic effects at apparent therapeutic plasma levels.
    Karlsson E
    Br Heart J; 1975 Jul; 37(7):731-40. PubMed ID: 1098684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agranulocytosis due to new sustained-release procainamide.
    Berger BE; Hauser DJ
    Am Heart J; 1983 Jun; 105(6):1035-6. PubMed ID: 6858823
    [No Abstract]   [Full Text] [Related]  

  • 8. Procainamide-induced agranulocytosis.
    Reidy TJ; Upshaw JD
    South Med J; 1984 Dec; 77(12):1582-4. PubMed ID: 6505768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agranulocytosis in a 12-year-old girl treated with procainamide.
    Gunay U; Honig GR
    Clin Pediatr (Phila); 1974 Sep; 13(9):728-30. PubMed ID: 4411903
    [No Abstract]   [Full Text] [Related]  

  • 10. Procainamide-induced agranulocytosis and thrombocytopenia.
    Rothman IK; Amorosi EL
    Arch Intern Med; 1979 Feb; 139(2):246-7. PubMed ID: 434983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide.
    Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T
    Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interaction of phenytoin with propranolol, procainamide and digoxin].
    Halawa B
    Pol Tyg Lek; 1985 Jul; 40(28):790-3. PubMed ID: 4059101
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacologic basis for the treatment of cardiac arrhythmias.
    Gelband H; Rosen MR
    Pediatrics; 1975 Jan; 55(1):59-67. PubMed ID: 1089243
    [No Abstract]   [Full Text] [Related]  

  • 14. Procainamide-induced agranulocytosis: report of two cases and review.
    Nagesh KG; Poulose KP; Tseng TH; Schadchehr A
    J Kans Med Soc; 1980 Jan; 81(1):18-24. PubMed ID: 6153211
    [No Abstract]   [Full Text] [Related]  

  • 15. Agranulocytosis secondary to extended-release procainamide: a case report and review of the literature. A case of agranulocytosis caused by procainamide in a patient who had undergone open-heart surgery.
    Malters PB; Salem AG
    S D J Med; 1987 Feb; 40(2):7-10. PubMed ID: 3470941
    [No Abstract]   [Full Text] [Related]  

  • 16. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of intravenous phenytoin, procainamide and practolol in the acute treatment of ventricular arrhythmias.
    Karlsson E; Kinman A; Sonnhag C
    Eur J Clin Pharmacol; 1977; 11(1):1-6. PubMed ID: 832652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
    Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA
    N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe neutropenia associated with sustained-release procainamide.
    Ellrodt AG; Murata GH; Riedinger MS; Stewart ME; Mochizuki C; Gray R
    Ann Intern Med; 1984 Feb; 100(2):197-201. PubMed ID: 6691661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.
    Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL
    Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.